Skip to main content

Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.

Publication ,  Journal Article
Sadun, RE; Sachsman, SM; Chen, X; Christenson, KW; Morris, WZ; Hu, P; Epstein, AL
Published in: Clin Cancer Res
July 1, 2007

PURPOSE: Despite lymphocyte infiltration of tumors and the activation of tumor-draining lymph nodes, malignant tumors are able to "escape" from both innate and adaptive immune responses. For immunotherapy to be successful, it must reverse these escape mechanisms, which necessitates explicit and tumor-specific elucidation of tumor escape strategies. RESEARCH DESIGN: To identify relevant escape mechanisms in murine tumors and in two corresponding human cancers, real-time reverse transcription-PCR was used to measure a panel of genes associated with T-cell activation and inhibition pathways. RESULTS: Comparative analysis of the expression levels of these immunomodulatory genes showed astonishing similarities in expression patterns between murine and human breast cancers but profound variability in the expression of immunomodulatory genes in colorectal cancers. For human ductal adenocarcinoma of the breast, down-regulation of dendritic cell maturation marker CD83 and T-cell activation gene CD28 was observed as well as a notable increase in the expression of the immunoinhibitory gene B7-H4. By contrast, colorectal adenocarcinoma cases showed high variability in tumor escape mechanisms, indicating a need to produce immune signatures for individual patients to identify appropriate immunotherapeutic targets. CONCLUSIONS: These results show that certain tumors, such as ductal carcinoma of the breast, show consistent immunologic abnormalities that can be used as targets for immunotherapy. These findings also show the importance and feasibility of determining the immune signatures of patients' tumors to select appropriate immunotherapeutic strategies. Ultimately, these results advocate for the determination of immune signatures as part of the customary repertoire of clinical diagnostics for cancer.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

July 1, 2007

Volume

13

Issue

13

Start / End Page

4016 / 4025

Location

United States

Related Subject Headings

  • V-Set Domain-Containing T-Cell Activation Inhibitor 1
  • Oncology & Carcinogenesis
  • Neoplasms
  • Mice, Inbred BALB C
  • Mice
  • Membrane Glycoproteins
  • Lymphocytes
  • Lymphocyte Activation
  • Immunotherapy
  • Immunoglobulins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sadun, R. E., Sachsman, S. M., Chen, X., Christenson, K. W., Morris, W. Z., Hu, P., & Epstein, A. L. (2007). Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res, 13(13), 4016–4025. https://doi.org/10.1158/1078-0432.CCR-07-0016
Sadun, Rebecca E., Suzanne M. Sachsman, Xiaoying Chen, Kamilee W. Christenson, William Z. Morris, Peisheng Hu, and Alan L. Epstein. “Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.Clin Cancer Res 13, no. 13 (July 1, 2007): 4016–25. https://doi.org/10.1158/1078-0432.CCR-07-0016.
Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, et al. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 1;13(13):4016–25.
Sadun, Rebecca E., et al. “Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.Clin Cancer Res, vol. 13, no. 13, July 2007, pp. 4016–25. Pubmed, doi:10.1158/1078-0432.CCR-07-0016.
Sadun RE, Sachsman SM, Chen X, Christenson KW, Morris WZ, Hu P, Epstein AL. Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. Clin Cancer Res. 2007 Jul 1;13(13):4016–4025.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

July 1, 2007

Volume

13

Issue

13

Start / End Page

4016 / 4025

Location

United States

Related Subject Headings

  • V-Set Domain-Containing T-Cell Activation Inhibitor 1
  • Oncology & Carcinogenesis
  • Neoplasms
  • Mice, Inbred BALB C
  • Mice
  • Membrane Glycoproteins
  • Lymphocytes
  • Lymphocyte Activation
  • Immunotherapy
  • Immunoglobulins